U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Carolina Liquid Chemistries Corp - 573596 - 11/02/2020
  1. Warning Letters

CLOSEOUT LETTER

Carolina Liquid Chemistries Corp MARCS-CMS 573596 —

Delivery Method:
VIA Electronic Mail
Recipient:
Recipient Name
Patricia A.G. Shugart, Philip Shugart
Recipient Title
Chief Operating Officer, CEO
Carolina Liquid Chemistries Corp

313 Gallimore Dairy Rd.
Greensboro, NC 27409
United States

pattigaull@aol.com
Issuing Office:
Office of Medical Devices and Radiological Health Operations Division 3/West

United States

Dear Ms. & Mr. Shugart,

The Food and Drug Administration has completed an evaluation of your corrective actions in response to a Warning Letter dated 7/31/2019. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Jessica Mu
Compliance Branch Director
Office of Medical Devices and Radiological Health Operations
Division 3/West

Back to Top